For a 78-year-old male with uncontrolled type 2 diabetes mellitus (HbA1c 9.3%), albuminuria, and estimated glomerular filtration rate 79 mL/min/1.73 m² who refuses insulin therapy, what non‑insulin treatment options should be pursued?

Add an SGLT2 Inhibitor Immediately—This Patient Needs Cardiorenal Protection Now

For this 78-year-old man refusing insulin, start an SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) as the priority intervention, then add a GLP-1 receptor agonist (dulaglutide, liraglutide, or semaglutide) if glycemic targets remain unmet after 3 months. 1

Why SGLT2 Inhibitors Are the Clear First Choice

Your patient has albuminuria (UACR 101 mg/g) and eGFR 79 mL/min/1.73 m²—this defines him as having diabetic kidney disease. The 2022 ADA/KDIGO consensus explicitly states: "An SGLT2i with proven kidney or cardiovascular benefit is recommended for patients with T2D, CKD, and eGFR ≥20 ml/min/1.73 m²." 1 This recommendation prioritizes mortality and morbidity reduction over glycemic control alone.

Specific SGLT2 Inhibitor Selection:

• Dapagliflozin 10 mg daily (no dose adjustment needed at eGFR 79) 1
• Empagliflozin 10 mg daily (no dose adjustment needed at eGFR 79) 1
• Canagliflozin 100-300 mg daily (alternative option) 1

These agents will:

• Reduce his risk of cardiovascular death by ~38% 2
• Slow eGFR decline and reduce progression to dialysis by 39-47% 2
• Lower albuminuria significantly 1
• Reduce HbA1c by 0.5-0.7% without hypoglycemia risk 2

Critical point: The kidney and cardiovascular benefits persist even when glucose-lowering efficacy diminishes at lower eGFRs 1. You're treating his kidney disease and cardiovascular risk, not just his glucose.

Second-Line: Add a GLP-1 Receptor Agonist

If HbA1c remains >8% after 3 months on SGLT2i + metformin (if tolerated) + glimepiride, add a GLP-1 receptor agonist with proven cardiovascular benefit 1:

Preferred Agents (in order of evidence strength):

1. Semaglutide (subcutaneous 0.5-1 mg weekly or oral 7-14 mg daily)—no dose adjustment needed at eGFR 79 1
2. Dulaglutide (1.5 mg weekly)—no dose adjustment needed 1
3. Liraglutide (1.2-1.8 mg daily)—no dose adjustment needed 1

These agents provide:

• Additional HbA1c reduction of 0.9-1.5% 1
• MACE reduction of 12-26% in cardiovascular outcomes trials 1
• Further albuminuria reduction and eGFR preservation 1
• Weight loss (beneficial for this patient) 3
• Notably, MACE reduction with liraglutide was significantly greater in patients with eGFR <60 mL/min/1.73 m² compared to those with higher eGFR 1

Managing the Glimepiride Problem

Taper and discontinue glimepiride once SGLT2i and GLP-1 RA are on board. 1 Here's why:

• Glimepiride carries high hypoglycemia risk, especially in older adults 1, 4
• The guideline states: "Initiate conservatively at 1 mg daily and titrate slowly to avoid hypoglycemia" in CKD 1—your patient is already on it, creating unnecessary risk
• Sulfonylureas provide no cardiovascular or renal protection 1
• Combining SGLT2i + GLP-1 RA will likely achieve better glycemic control than glimepiride alone, without hypoglycemia risk

Tapering protocol: Reduce glimepiride by 50% when starting SGLT2i, then discontinue entirely when adding GLP-1 RA (monitor glucose closely during transitions).

Addressing the Insulin Refusal

Validate his concerns, then reframe the conversation around kidney and heart protection rather than just glucose control. Most patients refuse insulin because they view it as:

• A sign of personal failure
• Too complex/burdensome
• Associated with weight gain and hypoglycemia

Your talking points:

• "The medications I'm recommending (SGLT2i and GLP-1 RA) are specifically proven to protect your kidneys and heart—your UACR has already improved from 251 to 101, and we want to keep that trend going"
• "These medications work differently than insulin—they help your body eliminate excess sugar through urine and improve how your body responds to its own insulin"
• "They don't cause low blood sugars like insulin can, and they may help you lose some weight"
• "Let's try this approach for 3-6 months. If we're not getting where we need to be, we can revisit insulin, but many patients do well without it when we use these newer medications"

The Practical Algorithm

Month 0 (Today):

• Start dapagliflozin 10 mg or empagliflozin 10 mg daily
• Reduce glimepiride dose by 50%
• Continue losartan 50 mg (excellent—RAAS inhibition + SGLT2i is the foundation) 1
• Continue metformin if tolerated (not mentioned in your plan—is he on it?)

Month 1:

• Check for genital mycotic infections (6% risk with SGLT2i, higher in women) 1
• Assess tolerability and adherence
• Discontinue glimepiride if glucose control stable

Month 3:

• Recheck HbA1c, UACR, eGFR
• If HbA1c >8%: Add GLP-1 RA (start with lowest dose, titrate up over 4-8 weeks to minimize GI side effects—nausea occurs in 15-20% but usually resolves) 1
• If HbA1c 7-8%: Continue current regimen
• If HbA1c <7%: Consider reducing other agents if hypoglycemia risk present

Month 6:

• Recheck HbA1c, UACR, eGFR
• If HbA1c still >8.5% despite SGLT2i + GLP-1 RA: Revisit insulin discussion with emphasis on basal insulin only (simpler regimen, once-daily dosing)

Common Pitfalls to Avoid

1. Don't wait for insulin failure to start SGLT2i—the kidney and cardiovascular benefits are independent of glucose lowering 1, 2

2. Don't continue glimepiride long-term—hypoglycemia risk in a 78-year-old with CKD is dangerous (falls, fractures, cognitive impairment) 4

3. Don't forget to counsel on SGLT2i-related genital hygiene—daily washing reduces mycotic infection risk 1

4. Don't stop SGLT2i if eGFR drops 5 mL/min initially—this is expected tubuloglomerular feedback and reverses over 3-9 months 2

5. Don't use ertugliflozin—it lacks the robust cardiovascular and renal outcomes data of dapagliflozin/empagliflozin 1

If He Still Refuses Everything

If the patient refuses both SGLT2i and GLP-1 RA (unlikely if you frame it as kidney/heart protection):

Fallback option: DPP-4 inhibitor (linagliptin—no dose adjustment needed at any eGFR) 1, 5

• Reduces HbA1c by 0.5-0.7% 5
• Low hypoglycemia risk (4-5%) 5
• But provides NO cardiovascular or renal protection 1—this is a significant compromise

Document clearly that you recommended guideline-directed therapy (SGLT2i + GLP-1 RA) for cardiorenal protection and the patient declined, choosing alternative therapy. This protects you medically and legally while respecting autonomy.

The Bottom Line

Your original plan was sound for glucose control, but it missed the bigger picture: this patient's kidneys and cardiovascular system are at high risk, and you have medications that directly address those risks. 1, 2 The insulin refusal is actually an opportunity to use superior agents that he's more likely to accept and that provide benefits insulin cannot match. SGLT2 inhibitors and GLP-1 receptor agonists are not "alternatives" to insulin in this context—they are superior first-line therapy for a patient with diabetic kidney disease, regardless of insulin use. 1, 6